avallier MC. Efficacy and safety of sustained-Р release alfuzosin 5 mg in patients with benign prostatic hyperplasia. ALGEBI Study Group. Р Eur Urol 1997;31(2):190-8. (Level 1b)Р .gov/pubmed/9076465Р16. van Kerrebroeck P, Jardin A, Laval KU, van Cangh P. Efficacy and safety of a new prolonged release Р formulation of alfuzosin 10 mg once daily versus afluzosin 2.5 mg thrice daily and placebo in patients Р with symptomatic benign prostatic hyperplasia. ALFORTI Study Group. Р Eur Urol 2000 Mar;37(3):306-13. (Level 1b)Р .gov/pubmed/10720857Р17. MacDonald R, Wilt TJ. Alfuzosin for treatment of lower urinary tract patible with benign Р prostatic hyperplasia: a systematic review of efficacy and adverse effects. Р Urology 2005 Oct;66(4):780-8. (Level 1a)Р .gov/pubmed/16230138Р10 UPDATE APRIL 2010
全文预览